P
ProHub
English 简体中文 繁體中文
Medium Profitability Product Strategy Market Entry Product Development

Fringe Science

#Healthcare #Pharmaceuticals
ProHub Comment

This case combines market analysis with clinical/qualitative factors to guide a high-stakes R&D investment decision. The candidate must balance quantitative profitability calculations against qualitative healthcare considerations (safety/efficacy profiles, formulary status, competitive positioning) and demonstrate how pricing strategy significantly impacts market share and formulary access in pharmaceutical markets.

Estimated Time 15 minutes
Difficulty Medium
Source Duke
50 / 100
Massive Dynamic is a multi-national pharmaceutical company. One of their assets, Cortexiphan, is an anti-infective that successfully treats three major types of hospital-born illness and is currently in Phase II clinical trials. Unfortunately, Massive Dynamic only has the capital to finance a Phase III clinical trial for one of the three illnesses with Cortexiphan treats. Walter Bishop, Chief Medical Officer of Massive Dynamic, has enlisted your help to decide which of the three possible indications for cortexiphan they should pursue to maximize profits over a five year-period post-launch.

Clarifying Information

  1. Drug is only likely to be approved in the US at this time
  2. Drug will be sold directly to hospitals by Massive Dynamic; therefore, no need to consider distribution channel costs, etc.
  3. No need to calculate based on NPV, just do total over five years w/out discounting
  4. Provide Exhibit 1 when asked about market size and/or competition
  5. Provide Exhibit 2 when asked about development costs or clinical profile
  6. Provide Exhibit 3 after an initial indication selected and pricing prompt given